Therapeutic Insights into Overcoming Therapy Resistance in BRAFV600E Melanoma
- Description
Although targeted cancer therapies have been successful, their efficacies are limited by the development of resistance driven by clonal evolution within tumors. This study developed a single-cell barcoding approach to comprehensively trace clonal dynamics and capture live lineage-coupled resistant cells for in-depth multi-omics analysis and functional exploration. They showed that heterogeneous clones, either preexisting or emerging from drug-tolerant persister cells, dominated resistance to vemurafenib in BRAFV600E melanoma. This dataset contains RNA sequencing, EPIC array, and whole-exome sequencing (WES) data.
The publication also includes supplementary data. The supplementary data contains several tables about editing outcomes of BC1 and BC2, 12,000 guide RNA sequences for making the 36 million barcodes, barcode counts and GFOLDs of A375 treated with PLX, and top barcodes for capture. In addition, there are tables that contains summary of copy number variations in the control and PLX-resistant subclones, gene expression (FPKM) in the control and PLX resistant subclones, somatic alterations, differentially-methylated positions, differentially-methylated genes, genes whose promoter methylation status correlated to RNA express change, and primers used.
Access
- Restrictions
-
Free to All
- Instructions
- All RNA sequencing and EPIC array data are deposited in Gene Expression Omnibus (GEO) and all WES data are deposited to Sequence Read Archive (SRA). Other data that support the findings of this study are available on PubMed Central (PMC) under Supplementary Materials.
- Grant Support
-
Defeat GBM Research Collaborative/National Brain Tumor Society